Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. obesity patient
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Obesity Patient Articles & Analysis

18 news found

Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by baseline HbA1c, HbA1c variability, and diabetes duration in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) ...

ByBayer AG


ReShape Lifesciences Announces 2017 Weight Loss Contest Winner

ReShape Lifesciences Announces 2017 Weight Loss Contest Winner

(NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the winners of its 2017 weight loss contest, which recognizes patients for their successful weight loss with the ReShape Balloon™. ...

ByReShape Lifesciences Inc.


ReShape Lifesciences Receives FDA 510(k) Clearance for the GIBI HD Calibration Tubes for use in Gastric and Bariatric Procedures

ReShape Lifesciences Receives FDA 510(k) Clearance for the GIBI HD Calibration Tubes for use in Gastric and Bariatric Procedures

The GIBI HD™ is also less traumatic to the patient, as it is intended to fit to the lesser curvature of the stomach more easily and quickly reach the pylorus. ...

ByReShape Lifesciences Inc.


ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

” “I am enthusiastic about the prospects for ReShape’s continued growth including its full suite of weight loss solutions, especially the Lap-Band® program and the demand generated by the multi-tiered direct-to-consumer (DTC) marketing campaign, thus far, which continues to be successful in driving patient engagement and filling surgeons’ pipeline for ...

ByReShape Lifesciences Inc.


Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder

Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder

Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration ...

ByCamurus AB


RareStone Group & Rhythm Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

RareStone Group & Rhythm Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

“A recent, non-interventional genotyping study in China showed that 2.6% of 4,000 patients with obesity had a genetic variant with known relevance to obesity, and we look forward to building on that study with several key providers of genetic testing in China. ...

ByRareStone Group


Velacur Data Presented at 2021 AASLD The Liver Meeting

Velacur Data Presented at 2021 AASLD The Liver Meeting

When measuring fatty liver disease in obese patients, a greater imaging depth (below subcutaneous fat and the liver capsule) results in a more accurate liver health assessment. ...

BySonic Incytes Medical Corp.


Exo Secures $220M in Series C Funding Round

Exo Secures $220M in Series C Funding Round

Uses such as predictive diagnostics could influence patients to make better choices and adopt healthier lifestyles prior to a confirmed diagnosis. ...

ByExo


Active Implants’ NUsurface Meniscus Implant Provides Statistically Superior Pain Relief

Active Implants’ NUsurface Meniscus Implant Provides Statistically Superior Pain Relief

“There is a significant need for new treatment options for patients who have persistent knee pain following a meniscectomy, which the NUsurface Implant may ...

ByActive Implants LLC


Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity

Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity

The aim of the present study was to compare PWV in patients with type 2 diabetes mellitus (T2DM) or obesity and healthy subjects in an outpatient setting. METHODS: A cross-sectional study was conducted in patients with obesity without T2DM (n = 37), T2DM without obesity (n = 40), ...

ByAxelife SAS


ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest

ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest

The ReShape Vest, a new investigational medical device for weight loss in obese patients, wraps around the stomach and is designed to emulate conventional bariatric surgery without permanent anatomical changes. ...

ByReShape Lifesciences Inc.


ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense Facilities

ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense Facilities

“We now are able to offer both our ReShape Balloon and ReShape vBloc to the over 400 DoD medical facilities that purchase through the Academy Medical network and to help the patients in those facilities to overcome obesity.” The ReShape Balloon uses advanced interconnected balloon technology designed to take up room in the stomach to help people with ...

ByReShape Lifesciences Inc.


ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium

ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium

(NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company and its products will be discussed during the Metabolic and Bariatric Sessions of the Minimally Invasive Surgery Symposium (MISS) taking place in Las Vegas from March 6-9, 2018. ...

ByReShape Lifesciences Inc.


ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai

ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai

While close to 30% of the global population is estimated to be obese, according to a University of Washington’s Institute for Health Metrics and Evaluation report from 2013, more than 66% of men and 60% of women in the UAE were estimated to be obese. ...

ByReShape Lifesciences Inc.


ReShape Medical, Inc. Completes $38 Million Series D Financing

ReShape Medical, Inc. Completes $38 Million Series D Financing

“With this momentum and the positive feedback we are receiving from physicians across the country, the Company is in a strong position to make the ReShape Procedure available to U.S. patients in need of a non-surgical option for weight loss and to achieve global leadership in non-surgical obesity treatment in the ...

ByReShape Lifesciences Inc.


ReShape Integrated Dual Balloon System to Fill Significant Gap in Obesity Treatment Spectrum

ReShape Integrated Dual Balloon System to Fill Significant Gap in Obesity Treatment Spectrum

While an estimated 50 million Americans are classified as obese with a BMI of 30-40, many neither qualify for nor want surgery, creating a significant unmet need for additional treatment options. ...

ByReShape Lifesciences Inc.


Obesity Primes the Colon for Cancer, According to NIH Study

Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. ...

ByNational Institute of Environmental Health Sciences (NIEHS)


Bisphenol A exposure can increase risk of diabetes and heart attacks

Bisphenol A exposure can increase risk of diabetes and heart attacks

The fat tissue was obtained from patients undergoing surgical procedures at The Christ Hospital in Cincinnati, Ohio. ...

ByEnvironmental News Network (ENN)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT